Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| WH1011PL | Other Identifier | Company internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Adherence to the dosing scheme is the principal element of COC efficiency. On the other hand noncompliance seemed to be an inseparable element of any oral treatment. The aim of the study is to evaluate in everyday practice the relation between dosage errors and indicated factors, potentially influencing the compliance with the dosing scheme.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill) | Drug | One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles. |
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of users showing noncompliant behaviors | 3 consecutive cycles (28-days per cycle) |
| Measure | Description | Time Frame |
|---|---|---|
| The characteristics of noncompliant behavior. | 3 consecutive cycles (28-days per cycle) | |
| The relation between noncompliant behavior and selected factors. | 3 consecutive cycles (28-days per cycle) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Gynecological practices ptients - starters or current users.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | Poland |
Not provided
| ID | Term |
|---|---|
| D010349 | Patient Compliance |
| ID | Term |
|---|---|
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| C534342 | drospirenone and ethinyl estradiol combination |
| D003277 | Contraceptives, Oral, Combined |
| D017135 | Desogestrel |
| ID | Term |
|---|---|
| D004338 | Drug Combinations |
| D004364 | Pharmaceutical Preparations |
| D003276 | Contraceptives, Oral |
| D003271 | Contraceptive Agents, Female |
Not provided
Not provided
Not provided
Not provided
Not provided
| D003270 | Contraceptive Agents |
| D012102 | Reproductive Control Agents |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D045506 | Therapeutic Uses |
| D009652 | Norpregnenes |
| D009650 | Norpregnanes |
| D009654 | Norsteroids |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |